MR
Merck & Co., Inc.
MRK Health Care · Pharmaceuticals & Biotechnology
Latest period 2026-06-30 · 39 filings on record
SHOWING
Fiscal years as the company filed them — each point is one closed year from its 10-K, ending on that year's own close. A year with no 10-K on file is assembled from its four quarters and labelled by its ending date instead; a year still open gets no column at all.
Ranked against Health Care · 51 peers
Each grade is a single reported quarter's assessment, never an average — a card shows the grade at the newest quarter in view, so it follows the period and range controls above. Latest scored quarter: 2026-06-30.
Growth
21st pct
▼−6 over range · as of 2025-12-31
Quality
71st pct
▲+52 over range · as of 2025-12-31
Safety
48th pct
▲+15 over range · as of 2025-12-31
OVERVIEWYoY Δ
Latest fiscal year · ending 2025-12-31 · green = improving · click a row to chart it
Revenue $65.0B +1.3% Gross margin 74.8% −1.5pp Operating margin — — Net margin 28.1% +1.4pp Net income $18.3B +6.6%
Debt / equity
0.94
+17.0%
EPS (diluted)
$7.28
+8.0%
EBITDA
—
—
Filings
Full history 0 match| Year | Q1 | Q2 | Q3 | FY |
|---|---|---|---|---|
| 2026 | 10-Q Q1 2026 | 10-Q Q2 2026 | no filing | no filing |
| 2025 | 10-Q Q1 2025 | 10-Q Q2 2025 | 10-Q Q3 2025 | 10-K FY 2025 |
| 2024 | 10-Q Q1 2024 | 10-Q Q2 2024 | 10-Q Q3 2024 | 10-K FY 2024 |
| 2023 | 10-Q Q1 2023 | 10-Q Q2 2023 | 10-Q Q3 2023 | 10-K FY 2023 |
| 2022 | 10-Q Q1 2022 | 10-Q Q2 2022 | 10-Q Q3 2022 | 10-K FY 2022 |
| 2021 | 10-Q Q1 2021 | 10-Q Q2 2021 | 10-Q Q3 2021 | 10-K FY 2021 |
| 2020 | 10-Q Q1 2020 | 10-Q Q2 2020 | 10-Q Q3 2020 | 10-K FY 2020 |
| 2019 | no filing | no filing | 10-Q Q3 2019 | 10-K FY 2019 |
No filings in this selection.
Widen the range or clear a filter.
Trends
Fiscal years as the company filed them
Revenue
| Period | Period end | Revenue |
|---|---|---|
| FY 2019 | 2019-12-31 | $39.1B |
| FY 2020 | 2020-12-31 | $41.5B |
| FY 2021 | 2021-12-31 | $48.7B |
| FY 2022 | 2022-12-31 | $59.3B |
| FY 2023 | 2023-12-31 | $60.1B |
| FY 2024 | 2024-12-31 | $64.2B |
| FY 2025 | 2025-12-31 | $65.0B |
Net income
| Period | Period end | Net income |
|---|---|---|
| FY 2019 | 2019-12-31 | $9.8B |
| FY 2020 | 2020-12-31 | $7.1B |
| FY 2021 | 2021-12-31 | $13.0B |
| FY 2022 | 2022-12-31 | $14.5B |
| FY 2023 | 2023-12-31 | $365.0M |
| FY 2024 | 2024-12-31 | $17.1B |
| FY 2025 | 2025-12-31 | $18.3B |
ZOOM
FY 2019
FY 2025
Grade history
Point-in-time: each period shows the grade of the quarter it ends at — grades are never summed or averaged across a window.
Growth
21
Quality
71
Safety
48
Hover to read every grade at a period · shared with the trends chart · axis fixed 0–100
| Period | Period end | Growth | Quality | Safety |
|---|---|---|---|---|
| FY 2019 | 2019-12-31 | not scored | not scored | not scored |
| FY 2020 | 2020-12-31 | not scored | not scored | not scored |
| FY 2021 | 2021-12-31 | not scored | not scored | not scored |
| FY 2022 | 2022-12-31 | not scored | not scored | not scored |
| FY 2023 | 2023-12-31 | 27 | 19 | 33 |
| FY 2024 | 2024-12-31 | 73 | 64 | 46 |
| FY 2025 | 2025-12-31 | 21 | 71 | 48 |